370880-76-5

Basic information

• Product Name: Benzyl allyl[2-(hydroxyimino)ethyl]carbamate
• Synonyms: Benzyl allyl[2-(hydroxyimino)ethyl]carbamate;Benzyl N-allyl-N-[2-(hydroxyimino)ethyl]carbamate;(E)-benzyl allyl(2-(hydroxyiMino)ethyl)carbaMate
• CAS NO: 370880-76-5
• Molecular Formula: C₁₃H₁₆N₂O₃
• Molecular Weight: 248.27774
• Mol File: 370880-76-5.mol

Chemical Properties

• Appearance: /
• Density: 1.08
• CAS DataBase Reference: Benzyl allyl[2-(hydroxyimino)ethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl allyl[2-(hydroxyimino)ethyl]carbamate(370880-76-5)
• EPA Substance Registry System: Benzyl allyl[2-(hydroxyimino)ethyl]carbamate(370880-76-5)

Safety Data

• Hazardous Substances Data: 370880-76-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Benzyl allyl[2-(hydroxyimino)ethyl]carbamate is used as a reagent in organic synthesis for the preparation of various chemical compounds.
Used as a Protecting Group for Amines:
In the synthesis of pharmaceuticals and agrochemicals, Benzyl allyl[2-(hydroxyimino)ethyl]carbamate serves as a protecting group for amines, which is crucial for preventing unwanted side reactions during the synthesis process.
Used in Peptide and Protein Modification:
Benzyl allyl[2-(hydroxyimino)ethyl]carbamate is utilized in the modification of peptides and proteins, allowing for the introduction of new functional groups or the alteration of existing ones to enhance their properties or functions.
Used in Bioconjugate Development:
This carbamate derivative is employed in the development of bioconjugates, which are hybrid molecules composed of biologically active components linked to other molecules, such as drugs, dyes, or nanoparticles, to improve their targeting, delivery, or therapeutic efficacy.
Used in Drug Delivery Systems:
Benzyl allyl[2-(hydroxyimino)ethyl]carbamate has potential applications in the design and development of drug delivery systems, where it can be used to modify the properties of drug carriers or to enhance the stability, solubility, or bioavailability of therapeutic agents.

Upstream product

• 569682-60-6 benzyl N-(2,2-dimethoxyethyl)-N-(prop-2-en-1-yl)carbamate 
• 114790-39-5 benzyl N-(2,2-dimethoxyethyl)carbamate 
• 501-53-1 benzyl chloroformate 
• 370880-75-4 benzyl N-(2-oxoethyl)-N-(prop-2-en-1-yl)carbamate 

Downstream Products

• 1017789-40-0 3-amino-4-hydroxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1255099-67-2 3-tert-butoxycarbonylamino-4-hydroxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1293940-34-7 3-tert-butoxycarbonylamino-4-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 370880-79-8 3-benzyl 6-(tert-butyl)-3,6-diazabicyclo[3.2.0]heptane-3,6-dicarboxylate 
• 370880-87-8 benzyl 3,6-diazabicyclo[3.2.0]heptane-3-carboxylate 

Relevant articles and documents

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR

The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).

TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE

The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5- fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro- phenyl]-5-methoxy-pyrazine-2-carboxamide.

TETRAHYDROPYRROLOTHIAZINE COMPOUNDS

The present invention provides a compound of Formula (I): wherein R is H or F; and A is:(A), (B), (C) or (D); or a pharmaceutically acceptable salt thereof.

TETRAHYDROPYRROLOTHIAZINE COMPOUNDS

The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel α4β2 nicotinic acetylcholine receptor selective agonists

A series of novel, potent neuronal nicotinic acetylcholine receptor (nAChR) ligands derived from 3,6-diazabicyclo[3.2.0]heptane have been synthesized and evaluated for binding affinity and agonist activity at the α4β2 nAChR subtype. Structure-activity relationship studies of these novel nAChR ligands focused on substitution effects on the pyridine ring, as well as stereo- and regiochemical influences of the 3,6-diazabicyclo[3.2.0]heptane core. Small 5-substituents on the pyridine ring had a modest impact on the binding affinities and functional activities. 6-Bromo, 6-chloro, and 6-methyl substituents on the pyridine ring led to increased binding affinities and improved functional activities. Most of the 6-N-pyridinyl-substituted 3,6-diazabicyclo[3.2.0]heptanes are selective for the α4β2 nAChR subtype. Compounds (1R,5S)-25, (1R,5S)-55, and (1R,5S)-56 were virtually inactive as agonists at the hα3β4 nAChR but retained potency and efficacy at the hα4β2 nAChR subtype. 3-N-Pyridinyl-substituted series demonstrated more complex SAR. (1R,5R)-39, (1R,5R)-41, and (1R,5R)-42 were found to be much more potent at the hα3β4 nAChR subtype, whereas (1R,5R)-38 and (1R,5R)-40 were very selective at the hα4β2 nAChR subtype. The SAR studies of these novel ligands led to the discovery of several compounds with interesting in vitro pharmacological profiles.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.